The IASLC 7th Latin American Conference on Lung Cancer (LALCA 2016) would like to thank the following sponsors and exhibitors for their continued support.
Guardant Health is focused on developing breakthrough diagnostics that can transform cancer into a manageable disease. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics and cancer diagnostics. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology.
The Denver-based International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 5,000 lung cancer specialists in 90 countries. IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high quality medicines that meet real needs, and today we remain true to that mission in all our work.
For 125 years, MSD has been a global health care leader working to help the world be well. Through our medicines, vaccines and biologic therapies, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships.
OncoDNA, The Cancer Theranostic Company, is the European leading oncology company providing solutions for cancer treatments, at the same time contributing to the knowledge applied to the fight against cancer. OncoDNA’s team is fully dedicated to help oncologists worldwide developing services to enable better treatment choices and treatment efficacy monitoring. The innovative approach of OncoDNA is based on its unique OncoDEEP-OncoTRACE combination.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.